Top Buys by Directors: Boudreaux's $2.4M Bet on ELV

Elevance Health Inc. (ELV) CEO Gail Boudreaux executed a notable insider purchase on July 18, 2025, acquiring 8,500 shares for $2.4 million at an average price of $286.94. This substantial investment by a top executive signals strong internal confidence, particularly as ELV shares recently traded down 7.2% on Friday to $282.91, now below Boudreaux's cost basis and near its 52-week low of $276.41, potentially indicating a perceived undervaluation by management despite recent market weakness.

Analysis

A significant insider transaction at Elevance Health (ELV) provides a strong bullish signal, as CEO Gail Boudreaux invested $2.4 million to acquire 8,500 shares at an average price of $286.94. This move suggests executive confidence in the firm's outlook or a belief that the stock is undervalued. The timing is particularly noteworthy, as the purchase occurred just before ELV shares experienced a significant 7.2% drop in a single trading session, closing at $282.91. This recent price action offers new investors an opportunity to acquire shares at a cost basis below that of the CEO. The stock's current level is near its 52-week low of $276.41, contrasting sharply with its 52-week high of $567.26, which may reinforce the management's view of undervaluation. Furthermore, the company provides a 2.3% annualized dividend yield, offering a source of income for investors.

Key Decisions for Investors

• Consider the CEO's $2.4 million purchase at a price above the current market level as a strong indicator of management's conviction in the stock's potential for appreciation.
• Evaluate the current share price, which is near its 52-week low and below the CEO's entry point, as a potentially attractive entry point for a long-term position.
• Factor the 2.3% annualized dividend yield into the total return calculation, which may provide a cushion against short-term price volatility.
• Given the sharp 7.2% single-day decline, investors should monitor for price stabilization or further catalysts before committing significant capital, despite the positive insider signal.